Effects of eicosepenteanoic acid on ventricular arrhythmia:a prospective,open-labeled,randomized controlled clinical trial

Effects of eicosepenteanoic acid on ventricular arrhythmia:a prospective,open-labeled,randomized controlled clinical trial - Treatment of ventricular arrhythmia by eicosepentanoic acid

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022506

Enrollment

200

Registered

2016-06-01

Start date

2012-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ventricular tachycardia ventricular fibrillation

Interventions

A:standard therapeutic drug B:standard therapeutic drug + eicosapentaenoic acid 1800mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with ICDs would experience 1 or more VT/VF

Exclusion criteria

Exclusion criteria: 1)Allergy against eicosapentaenoic acid 2)Patients with malignant neoplasm 3)Subjects whose doctor in charge do not agree to join the trial

Design outcomes

Primary

Measure	Time frame
The primary endpoint was appropriate ICD therapy for VT/VF confirmed by stored electrograms, or death from any cause.	—

Countries

Japan

Contacts

Public ContactTomohide Endo

Hirosaki University Graduate School of Medicine Department of Cardiology

endot526@hirosaki-u.ac.jp0172-39-5057

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026